Sonoma Pharmaceuticals (SNOA) Earning Somewhat Favorable News Coverage, Report Finds
News headlines about Sonoma Pharmaceuticals (NASDAQ:SNOA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sonoma Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.0653585699777 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Centene Corporation (CNC) registers a price change of 0.99% while Sonoma Pharmaceuticals, Inc. (SNOA) finishes … – Stocks Gallery (stocksgallery.com)
- Sonoma Pharmaceuticals Inc (SNOA) Shares Needle Moving 3.29% – Evergreen Caller (evergreencaller.com)
- Sonoma Pharmaceuticals’ (SNOA) CEO Jim Schutz on Fiscal Q1 2018 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) CFO Robert E. Miller Buys 2,264 Shares (americanbankingnews.com)
Shares of Sonoma Pharmaceuticals (SNOA) opened at 5.48 on Monday. The firm has a 50-day moving average price of $6.49 and a 200 day moving average price of $6.80. The company has a market capitalization of $23.60 million, a P/E ratio of 2.80 and a beta of 1.30. Sonoma Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $8.25.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.09. Sonoma Pharmaceuticals had a net margin of 54.36% and a negative return on equity of 44.24%. The company had revenue of $3.84 million during the quarter. On average, equities research analysts predict that Sonoma Pharmaceuticals will post ($2.67) earnings per share for the current year.
Separately, Maxim Group set a $10.00 target price on Sonoma Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Stock Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.